Work

What is the recommended duration of rituximab treatment for neuromyelitis optica?

Year: 2026

Type: article

Abstract: No direct evidence for the optimal duration of rituximab in neuromyelitis optica exists; indirect evidence suggests a practice of continuous treatment for at least five years, adapted based on patient-specific B-cell monitoring.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.24040000

Author: Tripdatabase

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7225465192

FWCI:

Cites:

Cited by:

Related to: 10